Antileishmanial potentials of azacitidine and along with meglumine antimoniate on Leishmania major: In silico prediction and in vitro analysis.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2023
Historique:
received: 13 04 2023
accepted: 28 08 2023
medline: 11 9 2023
pubmed: 8 9 2023
entrez: 8 9 2023
Statut: epublish

Résumé

This study aimed to investigate the in vitro and in silico antileishmanial activity of azacitidine (AZA) on Leishmania major promastigotes and amastigotes. The in silico method was used to evaluate the possibility of the interaction of AZA into the binding pocket of inducible nitric oxide synthase (iNOS), a leading defensive oxidative metabolite. Following that, in vitro anti-promastigote, and anti-amastigote activity of AZA was determined using an MTT assay and a macrophage model, respectively. Cytotoxic effects of AZA and meglumine antimoniate (MA) were also assessed by MTT assay on murine macrophages. All experiments were performed in triplicate. The results showed that AZA interacted with Ser133, Gln134, and Lys13 amino acids of iNOS, and the molecular docking score was obtained at -241.053 kcal/mol. AZA in combination with MA significantly (P<0.001) inhibited the growth rate of nonclinical promastigote (IC50 247.6±7.3 μM) and 8.5-fold higher of clinical intramacrophage amastigote stage (29.8±5.3 μM), compared to the untreated group. A significant upsurge of Th1 subsets and transcription genes and a meaningful decline in Th2 cytokines subclasses at the equivalent concentrations of AZA and MA was observed (P<0.001). The apoptosis effect of AZA along with MA was significantly induced on L. major in a dose-dependent manner (P<0.001). The present study demonstrated that AZA possesses antileishmanial activity in in vitro and in silico models. However, AZA combined with MA was more effective than AZA alone in inhibiting the growth rate of promastigotes and amastigotes of L. major. This study indicates that AZA in combination with MA demonstrated a potent antileishmanial mechanism, promoting immune response and enhancing an immunomodulatory role toward the Th1 pathway. This experimental study is a basic study for applying more knowledge about the mechanisms of AZA along with MA in animal models in the future.

Identifiants

pubmed: 37682979
doi: 10.1371/journal.pone.0291321
pii: PONE-D-23-08841
pmc: PMC10490874
doi:

Substances chimiques

Meglumine Antimoniate 75G4TW236W
Azacitidine M801H13NRU
Antiprotozoal Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0291321

Informations de copyright

Copyright: © 2023 Derakhshani et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

PLoS One. 2018 Feb 7;13(2):e0192236
pubmed: 29415078
Microb Pathog. 2019 Mar;128:162-170
pubmed: 30583021
F1000Res. 2017 May 26;6:750
pubmed: 28649370
PLoS Negl Trop Dis. 2021 Jan 28;15(1):e0009089
pubmed: 33507940
Int J Parasitol Drugs Drug Resist. 2018 Aug;8(2):213-222
pubmed: 29649665
Annu Rev Immunol. 2006;24:607-56
pubmed: 16551261
Int Immunopharmacol. 2020 Sep;86:106704
pubmed: 32590317
Clin Cancer Res. 2020 Jul 1;26(13):3371-3383
pubmed: 32054729
PLoS Negl Trop Dis. 2021 Sep 23;15(9):e0009734
pubmed: 34555016
Clin Epigenetics. 2015 Sep 11;7:98
pubmed: 26366235
Expert Rev Vaccines. 2021 Nov;20(11):1407-1418
pubmed: 34664543
PLoS Negl Trop Dis. 2021 May 13;15(5):e0009309
pubmed: 33983930
Blood. 2010 Jan 7;115(1):107-21
pubmed: 19887673
Exp Hematol. 2021 Jun;98:47-52.e6
pubmed: 33794295
Cells. 2021 Aug 19;10(8):
pubmed: 34440896
PLoS Negl Trop Dis. 2017 Aug 10;11(8):e0005739
pubmed: 28796782
Int Immunopharmacol. 2022 Jan;102:108400
pubmed: 34890999
Int J Mol Sci. 2019 Sep 15;20(18):
pubmed: 31540192
Cell Stem Cell. 2019 Jan 3;24(1):7-8
pubmed: 30609400
Int Immunopharmacol. 2019 Apr;69:321-327
pubmed: 30771740
Cytokine. 2002 Nov 24;20(4):154-62
pubmed: 12543079
Microb Pathog. 2018 Mar;116:124-129
pubmed: 29353004
Exp Hematol. 2008 Feb;36(2):149-57
pubmed: 18206726
Virol J. 2012 Jan 03;9:1
pubmed: 22214262
J Immunol. 2006 Apr 1;176(7):4083-93
pubmed: 16547244
Semin Hematol. 2021 Jan;58(1):45-55
pubmed: 33509443
Clin Epigenetics. 2016 Jun 21;8:71
pubmed: 27330573
Clin Microbiol Infect. 2011 Oct;17(10):1478-83
pubmed: 21933306
Int Immunopharmacol. 2021 Dec;101(Pt B):108274
pubmed: 34688150
Clin Immunol. 2003 Oct;109(1):89-102
pubmed: 14585280
PLoS One. 2012;7(5):e35671
pubmed: 22693548
Hum Cell. 2022 Mar;35(2):448-461
pubmed: 35064905
Front Microbiol. 2021 Jan 22;11:616922
pubmed: 33552027
Nucleic Acids Res. 2018 Jul 2;46(W1):W363-W367
pubmed: 29860391
Iran J Parasitol. 2019 Oct-Dec;14(4):521-533
pubmed: 32099555
Clin Exp Dermatol. 2022 Mar;47(3):516-521
pubmed: 34480806
Microb Pathog. 2019 Jan;126:368-378
pubmed: 30399441
J Antimicrob Chemother. 2019 Jun 1;74(6):1634-1641
pubmed: 30815688
Bioessays. 2021 Oct;43(10):e2100125
pubmed: 34463368
RSC Med Chem. 2022 Aug 26;13(9):1029-1043
pubmed: 36324493
Drug Des Devel Ther. 2017 Dec 22;12:25-40
pubmed: 29317800
Expert Rev Vaccines. 2021 Nov;20(11):1419-1430
pubmed: 34727814
Microb Pathog. 2012 Nov-Dec;53(5-6):219-26
pubmed: 22963864
BMC Genomics. 2007 Jan 05;8:7
pubmed: 17207281
Nucleic Acids Res. 2018 Jul 2;46(W1):W356-W362
pubmed: 29796670

Auteurs

Ali Derakhshani (A)

Research Center for Hydatid Disease in Iran, Kerman University of Medical Sciences, Kerman, Iran.

Iraj Sharifi (I)

Leishmaniasis Research Center, Kerman University of Medical Sciences, Kerman, Iran.

Ehsan Salarkia (E)

Leishmaniasis Research Center, Kerman University of Medical Sciences, Kerman, Iran.

Alireza Keyhani (A)

Leishmaniasis Research Center, Kerman University of Medical Sciences, Kerman, Iran.

Setareh Agha Kuchak Afshari (S)

Medical Mycology and Bacteriology Research Center, Kerman University of Medical Sciences, Kerman, Iran.

Behzad Iranmanesh (B)

Department of Dermatology, Afzalipour Hospital, Afzalipour Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran.

Mahdieh Lashkarizadeh (M)

Department of Pathology and Stem Cell Research Center, Kerman University of Medical Sciences, Kerman, Iran.

Hamid Nejad Biglari (H)

Department of Surgery, Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran.

Moslem Lari Najafi (M)

Pharmaceutical Sciences and Cosmetic Products Research Center, Kerman University of Medical Sciences, Kerman, Iran.

Mehdi Bamorovat (M)

Leishmaniasis Research Center, Kerman University of Medical Sciences, Kerman, Iran.

Articles similaires

Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice
Animals Tail Swine Behavior, Animal Animal Husbandry

Classifications MeSH